<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2022-21-5-21-28</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-1671</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Оценка эффективности иммунизации населения Санкт-Петербурга против новой коронавирусной инфекции (COVID-19)</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of the Effectiveness of Immunization Saint-Petersburg Population against COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6642-4717</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дарьина</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Dar'ina</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мария Геннадьевна Дарьина  – кандидат медицинских наук, доцент, заведующая городским координационным организационно-методическим отделом Санкт-Петербургского Медицинского информационно-аналитического центра; доцент кафедры эпидемиологии, паразитологии и  дезинфектологии Северо-Западного государственного медицинского университета имени И. И. Мечникова</p><p>198095, Санкт-Петербург, ул. Шкапина, д. 30</p></bio><bio xml:lang="en"><p>Mariya G. Dar’ina – Cand Sci. (Med.), Associate Professor, head of the city coordination organizational and methodological department, Saint Petersburg Medical Information and Analytical Centre; Associate Professor Epidemiology Department of North-western state medical university named after I.I. Mechnikov</p><p>30, st. Shkapina, St. Petersburg, 198095</p></bio><email xlink:type="simple">DaryinaM@spbmiac.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6765-5122</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Любимова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ljubimova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анна Викторовна Любимова  – профессор кафедры эпидемиологии, паразитологии и  дезинфектологии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Anna V. Lyubimova – Professor at the Epidemiology Department</p><p>St. Petersburg</p></bio><email xlink:type="simple">lubimova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5001-0210</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Светличная</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Svetlichnaja</surname><given-names>Yu. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юлия Сергеевна Светличная – начальник сектора госпитальной эпидемиологии городского координационного организационно-методического отдела Санкт-Петербургского Медицинского информационно-аналитического центра; доцент кафедры эпидемиологии, паразитологии и  дезинфектологии Северо-Западного государственного медицинского университета имени И. И. Мечникова</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Yuliya S. Svetlichnaya – head of the hospital epidemiology sector of the city Medical Information and Analytical Centre; Associate Professor of Epidemiology Department of North-western state medical university named after I.I. Mechnikov</p><p>St. Petersburg</p></bio><email xlink:type="simple">YSvetlichnaya@spbmiac.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7795-430X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Захватова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zahvatova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анастасия Сергеевна Захватова  – врач-методист сектора госпитальной эпидемиологии городского координационного организационно-методического отдела Санкт-Петербургского Медицинского информационно-аналитического центра; аспирант кафедры эпидемиологии, паразитологии и  дезинфектологии Северо-Западного государственного медицинского университета имени И. И. Мечникова</p><p>Санкт-Петербург </p></bio><bio xml:lang="en"><p>Anastasiya S. Zahvatova – physician-methodist of the hospital epidemiology sector of the St. Petersburg Medical Information and Analytical Centre; postgraduate of Epidemiology Department</p><p>St. Petersburg</p></bio><email xlink:type="simple">AZahvatova@spbmiac.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1334-8191</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Язенок</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Jazenok</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аркадий Витальевич Язенок – директор</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Arkadij V. Yazenok – director</p><p>St. Petersburg</p></bio><email xlink:type="simple">AYazenok@spbmiac.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2371-2460</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Харит</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Harit</surname><given-names>S. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сусанна Михайловна Харит – руководитель отдела профилактики инфекционных болезней клинического отдела</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Susanna M. Harit – head of the Department of prevention infectious diseases of the Clinical Department</p><p>St. Petersburg</p></bio><email xlink:type="simple">Kharit-s@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6890-8096</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Асланов</surname><given-names>Б. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Aslanov</surname><given-names>B. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Батырбек Исмелович Асланов – заведующий кафедрой эпидемиологии, паразитологии и дезинфектологии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Batyrbek I. Aslanov  – head of the Epidemiology Department</p><p>St. Petersburg</p></bio><email xlink:type="simple">batyra@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинский информационно-аналитический центр Комитета по здравоохранению г. Санкт-Петербурга;&#13;
Северо-Западный государственный медицинский университет им. И.И. Мечникова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medical Information and Analytical Center of the Health Committee of Saint Petersburg;&#13;
North-Western State Medical University named after I. I. Mechnikov of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Северо-Западный государственный медицинский университет им. И.И. Мечникова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University named after I. I. Mechnikov of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Медицинский информационно-аналитический центр Комитета по здравоохранению г. Санкт-Петербурга</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medical Information and Analytical Center of the Health Committee of Saint Petersburg</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Детский научно-клинический центр инфекционных болезней ФМБА</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pediatric Research and Clinical Center for Infectious Disease of the Federal Medical and Biological Agency</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>19</day><month>11</month><year>2022</year></pub-date><volume>21</volume><issue>5</issue><fpage>21</fpage><lpage>28</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Дарьина М.Г., Любимова А.В., Светличная Ю.С., Захватова А.С., Язенок А.В., Харит С.М., Асланов Б.И., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Дарьина М.Г., Любимова А.В., Светличная Ю.С., Захватова А.С., Язенок А.В., Харит С.М., Асланов Б.И.</copyright-holder><copyright-holder xml:lang="en">Dar'ina M.G., Ljubimova A.V., Svetlichnaja Y.S., Zahvatova A.S., Jazenok A.V., Harit S.M., Aslanov B.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/1671">https://www.epidemvac.ru/jour/article/view/1671</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Вакцинопрофилактика рассматривается как важнейшее и эффективнейшее средство защиты населения планеты от новой коронавирусной инфекции. Цель. Оценить эффективность иммунопрофилактики COVID-19 жителей Санкт-Петербурга.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. С использованием данных Федерального регистра лиц, больных COVID-19, и Федерального регистра вакцинированных от COVID-19 осуществлён ретроспективный эпидемиологический анализ кумулятивной инцидентности новой коронавирусной инфекции на территории Санкт-Петербурга за двенадцатимесячный период (с 1 декабря 2020 г. по 30 ноября 2021 г.) среди лиц старше 18 лет, вакцинированных (2 863 050 чел.) и не вакцинированных (1 558 030 чел.) от COVID-19 по состоянию на 01.12.2021.</p></sec><sec><title>Результаты</title><p>Результаты. Установлено, что риск заражения новой коронавирусной инфекцией среди вакцинированных лиц статистически значимо ниже, чем среди не вакцинированных RR = 0,11 (95% ДИ 0,109–0,110; p &lt; 0,001). Вакцинированные заболевшие COVID-19 реже нуждались в оказании медицинской помощи в стационарных условиях RR = 0,30 (95% ДИ 0,29–0,30; p &lt; 0,001). Также среди вакцинированных летальность была ниже RR = 0,35 (95% ДИ 0,33–0,37; p &lt; 0,001).</p></sec><sec><title>Заключение</title><p>Заключение. Установлена достоверная профилактическая эффективность применения отечественных вакцин в виде снижения уровня заболеваемости, частоты развития форм заболевания, требующих стационарного лечения; летальности среди вакцинированных лиц, а соответственно, и нагрузки на здравоохранение Санкт-Петербурга в целом.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. Vaccination is being replaced by the primary and most effective means of protecting the world's population from a new coronavirus infection.</p></sec><sec><title>Aim</title><p>Aim. Evaluation of the effectiveness of COVID-19 immunization in Saint-Petersburg.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: We retrospectively studied the epidemiological data on the cumulative incidence of COVID-19 in St. Petersburg among adults vaccinated (1,558,030 people) and unvaccinated (2,863,050 people) for period from December 01, 2020 to November 30, 2021 on 12.01.2021. We analyzed the data presented in the Federal Register of Persons with COVID-19 and the Federal Register of Those Vaccinated against COVID-19.</p></sec><sec><title>Results</title><p>Results. The risk of COVID-19 infection among vaccinated is statistically significantly lower than among unvaccinated RR = 0.11 (95% CI 0.109–0.110; p &lt; 0.001). Infected COVID-19 Vaccinated patients were less likely to need for emergency care/hospitalization RR = 0.30 (95% CI 0.29–0.30; p &lt; 0.001). Also among the vaccinated mortality was lower RR = 0.35 (95% CI 0.33–0.37; p &lt; 0.001).</p></sec><sec><title>Conclusion</title><p>Conclusion: We have established reliable preventive effectiveness of the use of domestic vaccines by reducing morbidity, the frequency of development of forms of the disease requiring inpatient treatment; reducing mortality among vaccinated and, accordingly, reducing the burden on the healthcare system of St. Petersburg.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>СOVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>вакцинация</kwd><kwd>эффективность</kwd><kwd>госпитализация</kwd><kwd>летальность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>immunoprophylaxis</kwd><kwd>vaccination</kwd><kwd>effectiveness</kwd><kwd>hospitalization</kwd><kwd>mortality</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397 (10275) p. 671–681. doi: 10.1016/S0140-6736(21)00234-8.</mixed-citation><mixed-citation xml:lang="en">Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397 (10275) p. 671–681. doi: 10.1016/S0140-6736(21)00234-8.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults. Lancet Reg Health Eur. 2021, 11:100241.</mixed-citation><mixed-citation xml:lang="en">Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults. Lancet Reg Health Eur. 2021, 11:100241.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC – United States, january 1 april 30, 2021. MMWR Morb Mortal Wkly Rep.2021, 28 may; 70 (21): р. 792–793.</mixed-citation><mixed-citation xml:lang="en">CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 vaccine breakthrough infections reported to CDC – United States, january 1 april 30, 2021. MMWR Morb Mortal Wkly Rep.2021, 28 may; 70 (21): р. 792–793.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021, р. 939–949. doi: 10.1016/S1473-3099(21)00224-3.</mixed-citation><mixed-citation xml:lang="en">Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021, р. 939–949. doi: 10.1016/S1473-3099(21)00224-3.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Dagan N, Barda N, Kepten E, et al. Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021, Apr 15; 384(15):1412–1423. doi: 10.1056/NEJMoa2101765.</mixed-citation><mixed-citation xml:lang="en">Dagan N, Barda N, Kepten E, et al. Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021, Apr 15; 384(15):1412–1423. doi: 10.1056/NEJMoa2101765.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tenforde MW, Embi PJ, Levy ME, et al. Influenza and Other Viruses in the Acutely Ill (IVY) Network. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326:2043–54. doi:10.1001/jama.2021.19499.</mixed-citation><mixed-citation xml:lang="en">Tenforde MW, Embi PJ, Levy ME, et al. Influenza and Other Viruses in the Acutely Ill (IVY) Network. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326:2043–54. doi:10.1001/jama.2021.19499.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jabłońska K, Aballéa S, Toumi M. The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. Public Health. 2021. Sep;198:230–237. DOI: 10.1016/j.puhe.2021.07.037</mixed-citation><mixed-citation xml:lang="en">Jabłońska K, Aballéa S, Toumi M. The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. Public Health. 2021. Sep;198:230–237. DOI: 10.1016/j.puhe.2021.07.037</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Xu S, Heing-Becker I, Zhang J, et al. COVID-19 Vaccination and Non-COVID-19 Mortality Risk Seven Integrated Health Care Organizations, United States, December 14, 2020July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1520–1524.</mixed-citation><mixed-citation xml:lang="en">Xu S, Heing-Becker I, Zhang J, et al. COVID-19 Vaccination and Non-COVID-19 Mortality Risk Seven Integrated Health Care Organizations, United States, December 14, 2020July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1520–1524.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Vaishya R, Gupta BM, Kappi M, et al. Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers – A multicenter cohort study. Diabetes Metab Syndr. 2021 Oct 4; 15 (6):102306.</mixed-citation><mixed-citation xml:lang="en">Vaishya R, Gupta BM, Kappi M, et al. Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers – A multicenter cohort study. Diabetes Metab Syndr. 2021 Oct 4; 15 (6):102306.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rovida F, Esposito GL, Rissone M, et al. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. Nat Commun. 2021 Oct 15; 12 (1): 6032.</mixed-citation><mixed-citation xml:lang="en">Rovida F, Esposito GL, Rissone M, et al. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. Nat Commun. 2021 Oct 15; 12 (1): 6032.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Liu C, Sun H, Yi Y, Shen W, et al. Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections – Risk Factors and Vaccine Effectiveness // medRxiv [Preprint]. 2021 Oct 7:2021.10.05.21264583.</mixed-citation><mixed-citation xml:lang="en">Liu C, Sun H, Yi Y, Shen W, et al. Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections – Risk Factors and Vaccine Effectiveness // medRxiv [Preprint]. 2021 Oct 7:2021.10.05.21264583.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059–1062.</mixed-citation><mixed-citation xml:lang="en">Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059–1062.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Naito T, Yan Yan,Yoko Tabe, et al. Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan. Hum Vaccin Immunother. 2021 Oct 6:1–2.</mixed-citation><mixed-citation xml:lang="en">Naito T, Yan Yan,Yoko Tabe, et al. Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan. Hum Vaccin Immunother. 2021 Oct 6:1–2.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021 Jun 10; 384(23):2212–2218.</mixed-citation><mixed-citation xml:lang="en">Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021 Jun 10; 384(23):2212–2218.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jain VK, Yengar KP, Ish P. Elucidating causes of COVID-19 infection and related deaths after vaccination. Diabetes Metab Syndr. 2021 Sep-Oct; 15 (5): 102212. doi: 10.1016/j.dsx.2021.102212. Epub 2021 Jul 15. 1</mixed-citation><mixed-citation xml:lang="en">Jain VK, Yengar KP, Ish P. Elucidating causes of COVID-19 infection and related deaths after vaccination. Diabetes Metab Syndr. 2021 Sep-Oct; 15 (5): 102212. doi: 10.1016/j.dsx.2021.102212. Epub 2021 Jul 15. 1</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wang R, Chen J, Hozumi Yu, et al. Emerging vaccine-breakthrough SARS-CoV-2 variants. ArXiv. 2021 Sep 9: arXiv:2109.04509v1.</mixed-citation><mixed-citation xml:lang="en">Wang R, Chen J, Hozumi Yu, et al. Emerging vaccine-breakthrough SARS-CoV-2 variants. ArXiv. 2021 Sep 9: arXiv:2109.04509v1.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, WangQQ, Pamela BD, et al. Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry. 2021 Oct 5.</mixed-citation><mixed-citation xml:lang="en">Wang L, WangQQ, Pamela BD, et al. Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry. 2021 Oct 5.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
